In multiple instances, researchers have demonstrated that diminished or absent CDX2 expression is associated with the aggressive behavior of CRC, characterized by invasive and poorly differentiated tumors, as well as low overall survival (OS) and disease-free progression (DFS) rates [7,9,21,31,34,36,37,38]. The gene discussed is CDX2; the disease is colorectal carcinoma.